{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:53:52Z","timestamp":1765475632402,"version":"3.48.0"},"reference-count":54,"publisher":"Innovative Healthcare Institute","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>To date SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a member of the Coronaviridae family, has infected more than 40 million people worldwide. A second wave of SARS-CoV-2 infection is aggressively surging. The clinical worsening of SARS-CoV-2 infection appears to be strictly associated with comorbidities, which can be used to establish an intrinsic patient network whose molecular profile is pivotal for identifying and successfully treating populations at risk. Herein, we focus on the direct interaction between SARS-CoV-2 and virus-associated cancers, exploring the critical role of interleukin-6 (IL-6) as a mediator of this complex cross talk. IL-6 production is enhanced in diverse viral infections ranging from human papilloma virus (HPV) to hepatitis B virus (HBV), human immunodeficiency virus (HIV), and SARS-CoV-2 infection. High systemic levels of IL-6 are associated with viral persistence and poor clinical outcomes in SARS-CoV-2\u2013infected patients. Blockade of IL-6\/IL-6R, using specific molecules, is under investigation in active clinical trials for the treatment of patients with SARS-CoV-2. Although the data are as yet inconclusive, they pave the way for selective targeting of crucial cytokine-activated aberrant signaling in SARS-CoV-2 infection.<\/jats:p>","DOI":"10.36401\/jipo-20-27","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T16:44:51Z","timestamp":1611938691000},"page":"79-85","source":"Crossref","is-referenced-by-count":4,"title":["Does Interleukin-6 Bridge SARS-CoV-2 With Virus-Associated Cancers?"],"prefix":"10.36401","volume":"4","author":[{"given":"Aldo","family":"Venuti","sequence":"first","affiliation":[{"name":"HPV-Unit, UOSD (Simple Departmental Operational Unit) Tumor Immunology and Immunotherapy, IRCCS (Scientific Institute for Research, Hospitalization and Healthcare) Regina Elena National Cancer Institute, Rome, Italy"},{"name":"UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Donzelli","sequence":"additional","affiliation":[{"name":"Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Nistic\u00f2","sequence":"additional","affiliation":[{"name":"UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[{"name":"Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[{"name":"Scientific Direction, IRCSS Regina Elena National Cancer Institute, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22027","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"2021051818503243700_i2590-017X-4-2-79-b01","doi-asserted-by":"crossref","unstructured":"Van de Haar\n              J,\n            \n            \n              Hoes\n              LR,\n            \n            \n              Coles\n              CE,\n            \n            et al.\n          \n          Caring for patients with cancer in the COVID-19 era.\n\t\t\t\t\tNat Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\t665\u2013\n\t\t\t\t\t667.","DOI":"10.1038\/s41591-020-0874-8"},{"key":"2021051818503243700_i2590-017X-4-2-79-b02","doi-asserted-by":"crossref","unstructured":"Siddiqi\n              HK,\n            \n            \n              Mehra\n              MR.\n            \n          \n          COVID-19 illness in native and immunosuppressed states: a clinical therapeutic staging proposal.\n\t\t\t\t\tJ Heart Lung Transplant.\n\t\t\t\t\t2020;\n\t\t\t\t\t39:\n\t\t\t\t\t405\u2013\n\t\t\t\t\t407.","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"2021051818503243700_i2590-017X-4-2-79-b03","doi-asserted-by":"crossref","unstructured":"Magro\n              G.\n            \n          \n          SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the \u2018culprit lesion' of ARDS onset\u2014what is there besides Tocilizumab: SGP130Fc.\n\t\t\t\t\tCytokine X.\n\t\t\t\t\t2020;\n\t\t\t\t\t2:\n\t\t\t\t\t100029.","DOI":"10.1016\/j.cytox.2020.100029"},{"key":"2021051818503243700_i2590-017X-4-2-79-b04","doi-asserted-by":"crossref","unstructured":"Kishimoto\n              T.\n            \n          \n          Interleukin-6: discovery of a pleiotropic cytokine.\n\t\t\t\t\tArthritis Res Ther.\n\t\t\t\t\t2006;\n\t\t\t\t\t8:\n\t\t\t\t\tS2.","DOI":"10.1186\/ar1916"},{"key":"2021051818503243700_i2590-017X-4-2-79-b05","doi-asserted-by":"crossref","unstructured":"Kumar\n              H,\n            \n            \n              Kawai\n              T,\n            \n            \n              Akira\n              S.\n            \n          \n          Pathogen recognition by the innate immune system.\n\t\t\t\t\tInt Rev Immunol.\n\t\t\t\t\t2011;\n\t\t\t\t\t30:\n\t\t\t\t\t16\u2013\n\t\t\t\t\t34.","DOI":"10.3109\/08830185.2010.529976"},{"key":"2021051818503243700_i2590-017X-4-2-79-b06","doi-asserted-by":"crossref","unstructured":"Kang\n              S,\n            \n            \n              Tanaka\n              T,\n            \n            \n              Narazaki\n              M,\n            \n            \n              Kishimoto\n              T.\n            \n          \n          Targeting interleukin-6 signaling in clinic.\n\t\t\t\t\tImmunity.\n\t\t\t\t\t2019;\n\t\t\t\t\t16;\n\t\t\t\t\t50:\n\t\t\t\t\t1007\u2013\n\t\t\t\t\t1023.","DOI":"10.1016\/j.immuni.2019.03.026"},{"key":"2021051818503243700_i2590-017X-4-2-79-b07","doi-asserted-by":"crossref","unstructured":"Paonessa\n              G,\n            \n            \n              Graziani\n              R,\n            \n            \n              De Serio\n              A,\n            \n            et al.\n          \n          Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.\n\t\t\t\t\tEMBO J.\n\t\t\t\t\t1995;\n\t\t\t\t\t14:\n\t\t\t\t\t1942\u2013\n\t\t\t\t\t1951.","DOI":"10.1002\/j.1460-2075.1995.tb07186.x"},{"key":"2021051818503243700_i2590-017X-4-2-79-b08","doi-asserted-by":"crossref","unstructured":"Yokota\n              S,\n            \n            \n              Kishimoto\n              T.\n            \n          \n          Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.\n\t\t\t\t\tExpert Rev Clin Immunol.\n\t\t\t\t\t2010;\n\t\t\t\t\t6:\n\t\t\t\t\t735\u2013\n\t\t\t\t\t743.","DOI":"10.1586\/eci.10.41"},{"key":"2021051818503243700_i2590-017X-4-2-79-b09","doi-asserted-by":"crossref","unstructured":"Kotch\n              C,\n            \n            \n              Barrett\n              D,\n            \n            \n              Teachey\n              DT.\n            \n          \n          Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.\n\t\t\t\t\tExpert Rev Clin Immunol.\n\t\t\t\t\t2019;\n\t\t\t\t\t15:\n\t\t\t\t\t813\u2013\n\t\t\t\t\t822.","DOI":"10.1080\/1744666X.2019.1629904"},{"key":"2021051818503243700_i2590-017X-4-2-79-b10","doi-asserted-by":"crossref","unstructured":"Zhao\n              M,\n            \n            \n              Lu\n              J,\n            \n            \n              Tang\n              Y,\n            \n            et al.\n          \n          Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies.\n\t\t\t\t\tEur J Clin Pharmacol.\n\t\t\t\t\t2020;\n\t\t\t\t\t13:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t9.","DOI":"10.1007\/s00228-020-03017-5"},{"key":"2021051818503243700_i2590-017X-4-2-79-b11","doi-asserted-by":"crossref","unstructured":"Velazquez-Salinas\n              L,\n            \n            \n              Verdugo-Rodriguez\n              A,\n            \n            \n              Rodriguez\n              LL,\n            \n            \n              Borca\n              MV.\n            \n          \n          The role of interleukin 6 during viral infections.\n\t\t\t\t\tFront Microbiol.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t1057.","DOI":"10.3389\/fmicb.2019.01057"},{"key":"2021051818503243700_i2590-017X-4-2-79-b12","doi-asserted-by":"crossref","unstructured":"Tanaka\n              T,\n            \n            \n              Narazaki\n              M,\n            \n            \n              Kishimoto\n              T.\n            \n          \n          IL-6 in inflammation, immunity, and disease.\n\t\t\t\t\tCold Spring Harb Perspect Biol.\n\t\t\t\t\t2014;\n\t\t\t\t\t6:\n\t\t\t\t\ta016295.","DOI":"10.1101\/cshperspect.a016295"},{"key":"2021051818503243700_i2590-017X-4-2-79-b13","doi-asserted-by":"crossref","unstructured":"Mauer\n              J,\n            \n            \n              Denson\n              JL,\n            \n            \n              Br\u00fcning\n              JC.\n            \n          \n          Versatile functions for IL-6 in metabolism and cancer.\n\t\t\t\t\tTrends Immunol.\n\t\t\t\t\t2015;\n\t\t\t\t\t36:\n\t\t\t\t\t92\u2013\n\t\t\t\t\t101.","DOI":"10.1016\/j.it.2014.12.008"},{"key":"2021051818503243700_i2590-017X-4-2-79-b14","doi-asserted-by":"crossref","unstructured":"Dienz\n              O,\n            \n            \n              Rincon\n              M.\n            \n          \n          The effects of IL-6 on CD4 T cell responses.\n\t\t\t\t\tClin Immunol.\n\t\t\t\t\t2009;\n\t\t\t\t\t130:\n\t\t\t\t\t27\u2013\n\t\t\t\t\t33.","DOI":"10.1016\/j.clim.2008.08.018"},{"key":"2021051818503243700_i2590-017X-4-2-79-b15","doi-asserted-by":"crossref","unstructured":"Kopf\n              M,\n            \n            \n              Baumann\n              H,\n            \n            \n              Freer\n              G,\n            \n            et al.\n          \n          Impaired immune and acute-phase responses in interleukin-6-deficient mice.\n\t\t\t\t\tNature.\n\t\t\t\t\t1994;\n\t\t\t\t\t368:\n\t\t\t\t\t339\u2013\n\t\t\t\t\t342.","DOI":"10.1038\/368339a0"},{"key":"2021051818503243700_i2590-017X-4-2-79-b16","doi-asserted-by":"crossref","unstructured":"Harker\n              JA,\n            \n            \n              Lewis\n              GM,\n            \n            \n              Mack\n              L,\n            \n            \n              Zuniga\n              EI.\n            \n          \n          Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection.\n\t\t\t\t\tScience.\n\t\t\t\t\t2011;\n\t\t\t\t\t334:\n\t\t\t\t\t825\u2013\n\t\t\t\t\t829.","DOI":"10.1126\/science.1208421"},{"key":"2021051818503243700_i2590-017X-4-2-79-b17","doi-asserted-by":"crossref","unstructured":"Lauder\n              SN,\n            \n            \n              Jones\n              E,\n            \n            \n              Smart\n              K,\n            \n            et al.\n          \n          Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology.\n\t\t\t\t\tEur J Immunol.\n\t\t\t\t\t2013;\n\t\t\t\t\t43:\n\t\t\t\t\t2613\u2013\n\t\t\t\t\t2625.","DOI":"10.1002\/eji.201243018"},{"key":"2021051818503243700_i2590-017X-4-2-79-b18","doi-asserted-by":"crossref","unstructured":"Yang\n              ML,\n            \n            \n              Wang\n              CT,\n            \n            \n              Yang\n              SJ,\n            \n            et al.\n          \n          IL-6 ameliorates acute lung injury in influenza virus infection.\n\t\t\t\t\tSci Rep.\n\t\t\t\t\t2017;\n\t\t\t\t\t7:\n\t\t\t\t\t43829.","DOI":"10.1038\/srep43829"},{"key":"2021051818503243700_i2590-017X-4-2-79-b19","doi-asserted-by":"crossref","unstructured":"Kawai\n              T,\n            \n            \n              Akira\n              S.\n            \n          \n          The role of pattern-recognition receptors in innate immunity: update on toll-like receptors.\n\t\t\t\t\tNat Immunol.\n\t\t\t\t\t2010;\n\t\t\t\t\t11:\n\t\t\t\t\t373\u2013\n\t\t\t\t\t384.","DOI":"10.1038\/ni.1863"},{"key":"2021051818503243700_i2590-017X-4-2-79-b20","doi-asserted-by":"crossref","unstructured":"Cussigh\n              A,\n            \n            \n              Falleti\n              E,\n            \n            \n              Fabris\n              C,\n            \n            et al.\n          \n          Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C.\n\t\t\t\t\tImmunogenetics.\n\t\t\t\t\t2011;\n\t\t\t\t\t63:\n\t\t\t\t\t33\u2013\n\t\t\t\t\t41.","DOI":"10.1007\/s00251-010-0491-7"},{"key":"2021051818503243700_i2590-017X-4-2-79-b21","doi-asserted-by":"crossref","unstructured":"Kuo\n              TM,\n            \n            \n              Hu\n              CP,\n            \n            \n              Chen\n              YL,\n            \n            et al.\n          \n          HBV replication is significantly reduced by IL-6.\n\t\t\t\t\tJ Biomed Sci.\n\t\t\t\t\t2009;\n\t\t\t\t\t16:\n\t\t\t\t\t41.","DOI":"10.1186\/1423-0127-16-41"},{"key":"2021051818503243700_i2590-017X-4-2-79-b22","doi-asserted-by":"crossref","unstructured":"Palumbo\n              GA,\n            \n            \n              Scisciani\n              C,\n            \n            \n              Pediconi\n              N,\n            \n            et al.\n          \n          IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2015;\n\t\t\t\t\t10:\n\t\t\t\t\te0142599.","DOI":"10.1371\/journal.pone.0142599"},{"key":"2021051818503243700_i2590-017X-4-2-79-b23","doi-asserted-by":"crossref","unstructured":"Bouezzedine\n              F,\n            \n            \n              Fardel\n              O,\n            \n            \n              Gripon\n              P.\n            \n          \n          Interleukin 6 inhibits HBV entry through NTCP down regulation.\n\t\t\t\t\tVirology.\n\t\t\t\t\t2015;\n\t\t\t\t\t481:\n\t\t\t\t\t34\u2013\n\t\t\t\t\t42.","DOI":"10.1016\/j.virol.2015.02.026"},{"key":"2021051818503243700_i2590-017X-4-2-79-b24","doi-asserted-by":"crossref","unstructured":"Ohno\n              H,\n            \n            \n              Kaneko\n              S,\n            \n            \n              Kobayashi\n              K,\n            \n            \n              Murakami\n              S.\n            \n          \n          Human hepatitis B virus enhancer 1 is responsive to human interleukin-6.\n\t\t\t\t\tJ Med Virol.\n\t\t\t\t\t1997;\n\t\t\t\t\t52:\n\t\t\t\t\t413\u2013\n\t\t\t\t\t418.","DOI":"10.1002\/(SICI)1096-9071(199708)52:4<413::AID-JMV12>3.0.CO;2-H"},{"key":"2021051818503243700_i2590-017X-4-2-79-b25","unstructured":"Lee\n              Y,\n            \n            \n              Park\n              US,\n            \n            \n              Choi\n              I,\n            \n            et al.\n          \n          Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t1998;\n\t\t\t\t\t4:\n\t\t\t\t\t1711\u2013\n\t\t\t\t\t1717."},{"key":"2021051818503243700_i2590-017X-4-2-79-b26","doi-asserted-by":"crossref","unstructured":"Waris\n              G,\n            \n            \n              Siddiqui\n              A.\n            \n          \n          Interaction between STAT-3 and HNF-3 leads to the activation of liver-specific hepatitis B virus enhancer 1 function.\n\t\t\t\t\tJ Virol.\n\t\t\t\t\t2002;\n\t\t\t\t\t76:\n\t\t\t\t\t2721\u2013\n\t\t\t\t\t2729.","DOI":"10.1128\/JVI.76.6.2721-2729.2002"},{"key":"2021051818503243700_i2590-017X-4-2-79-b27","doi-asserted-by":"crossref","unstructured":"Dell'Oste\n              V,\n            \n            \n              Azzimonti\n              B,\n            \n            \n              Mondini\n              M,\n            \n            et al.\n          \n          Altered expression of UVB-induced cytokines in human papillomavirus-immortalized epithelial cells.\n\t\t\t\t\tJ Gen Virol.\n\t\t\t\t\t2008;\n\t\t\t\t\t89(pt 10):\n\t\t\t\t\t2461\u2013\n\t\t\t\t\t2466.","DOI":"10.1099\/vir.0.83586-0"},{"key":"2021051818503243700_i2590-017X-4-2-79-b28","doi-asserted-by":"crossref","unstructured":"Artaza-Irigaray\n              C,\n            \n            \n              Molina-Pineda\n              A,\n            \n            \n              Aguilar-Lemarroy\n              A,\n            \n            et al.\n          \n          E6\/E7 and E6(*) from HPV16 and HPV18 upregulate IL-6 expression independently of p53 in keratinocytes.\n\t\t\t\t\tFront Immunol.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t1676.","DOI":"10.3389\/fimmu.2019.01676"},{"key":"2021051818503243700_i2590-017X-4-2-79-b29","doi-asserted-by":"crossref","unstructured":"Wu\n              W,\n            \n            \n              Dietze\n              KK,\n            \n            \n              Gibbert\n              K,\n            \n            et al.\n          \n          TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection.\n\t\t\t\t\tSci Rep.\n\t\t\t\t\t2015;\n\t\t\t\t\t5:\n\t\t\t\t\t10501.","DOI":"10.1038\/srep10501"},{"key":"2021051818503243700_i2590-017X-4-2-79-b30","doi-asserted-by":"crossref","unstructured":"Hou\n              W,\n            \n            \n              Jin\n              YH,\n            \n            \n              Kang\n              HS,\n            \n            \n              Kim\n              BS.\n            \n          \n          Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function.\n\t\t\t\t\tJ Virol.\n\t\t\t\t\t2014;\n\t\t\t\t\t88:\n\t\t\t\t\t8479\u2013\n\t\t\t\t\t8489.","DOI":"10.1128\/JVI.00724-14"},{"key":"2021051818503243700_i2590-017X-4-2-79-b31","doi-asserted-by":"crossref","unstructured":"Hou\n              W,\n            \n            \n              Kang\n              HS,\n            \n            \n              Kim\n              BS.\n            \n          \n          Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection.\n\t\t\t\t\tJ Exp Med.\n\t\t\t\t\t2009;\n\t\t\t\t\t206:\n\t\t\t\t\t313\u2013\n\t\t\t\t\t328.","DOI":"10.1084\/jem.20082030"},{"key":"2021051818503243700_i2590-017X-4-2-79-b32","doi-asserted-by":"crossref","unstructured":"Martinez\n              NE,\n            \n            \n              Sato\n              F,\n            \n            \n              Kawai\n              E,\n            \n            et al.\n          \n          Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis.\n\t\t\t\t\tFuture Virol.\n\t\t\t\t\t2012;\n\t\t\t\t\t7:\n\t\t\t\t\t593\u2013\n\t\t\t\t\t608.","DOI":"10.2217\/fvl.12.44"},{"key":"2021051818503243700_i2590-017X-4-2-79-b33","doi-asserted-by":"crossref","unstructured":"Jin\n              YH,\n            \n            \n              Hou\n              W,\n            \n            \n              Kang\n              HS,\n            \n            et al.\n          \n          The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus.\n\t\t\t\t\tJ Virol.\n\t\t\t\t\t2013;\n\t\t\t\t\t87:\n\t\t\t\t\t11538\u2013\n\t\t\t\t\t11551.","DOI":"10.1128\/JVI.01967-13"},{"key":"2021051818503243700_i2590-017X-4-2-79-b34","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nrich\n              G,\n            \n            \n              Raftery\n              MJ.\n            \n          \n          The PD-1\/PD-L1 axis and virus infections: a delicate balance.\n\t\t\t\t\tFront Cell Infect Microbiol.\n\t\t\t\t\t2019;\n\t\t\t\t\t9:\n\t\t\t\t\t207.","DOI":"10.3389\/fcimb.2019.00207"},{"key":"2021051818503243700_i2590-017X-4-2-79-b35","doi-asserted-by":"crossref","unstructured":"Hsueh\n              PR,\n            \n            \n              Chen\n              PJ,\n            \n            \n              Hsiao\n              CH,\n            \n            et al.\n          \n          Patient data, early SARS epidemic, Taiwan.\n\t\t\t\t\tEmerg Infect Dis.\n\t\t\t\t\t2004;\n\t\t\t\t\t10:\n\t\t\t\t\t489\u2013\n\t\t\t\t\t493.","DOI":"10.3201\/eid1003.030571"},{"key":"2021051818503243700_i2590-017X-4-2-79-b36","doi-asserted-by":"crossref","unstructured":"Huang\n              C,\n            \n            \n              Wang\n              Y,\n            \n            \n              Li\n              X,\n            \n            et al.\n          \n          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2020;\n\t\t\t\t\t395:\n\t\t\t\t\t497\u2013\n\t\t\t\t\t506.","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2021051818503243700_i2590-017X-4-2-79-b37","doi-asserted-by":"crossref","unstructured":"Torre\n              D,\n            \n            \n              Zeroli\n              C,\n            \n            \n              Giola\n              M,\n            \n            et al.\n          \n          Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t1994;\n\t\t\t\t\t18:\n\t\t\t\t\t194\u2013\n\t\t\t\t\t198.","DOI":"10.1093\/clinids\/18.2.194"},{"key":"2021051818503243700_i2590-017X-4-2-79-b38","doi-asserted-by":"crossref","unstructured":"Spanakis\n              NE,\n            \n            \n              Garinis\n              GA,\n            \n            \n              Alexopoulos\n              EC,\n            \n            et al.\n          \n          Cytokine serum levels in patients with chronic HCV infection.\n\t\t\t\t\tJ Clin Lab Anal.\n\t\t\t\t\t2002;\n\t\t\t\t\t16:\n\t\t\t\t\t40\u2013\n\t\t\t\t\t46.","DOI":"10.1002\/jcla.2060"},{"key":"2021051818503243700_i2590-017X-4-2-79-b39","doi-asserted-by":"crossref","unstructured":"Borges\n              \u00c1,\n            \n            \n              O'Connor\n              JL,\n            \n            \n              Phillips\n              AN,\n            \n            et al.\n          \n          Factors associated with plasma IL-6 levels during HIV infection.\n\t\t\t\t\tJ Infect Dis.\n\t\t\t\t\t2015;\n\t\t\t\t\t212:\n\t\t\t\t\t585\u2013\n\t\t\t\t\t595.","DOI":"10.1093\/infdis\/jiv123"},{"key":"2021051818503243700_i2590-017X-4-2-79-b40","doi-asserted-by":"crossref","unstructured":"Chirathaworn\n              C,\n            \n            \n              Poovorawan\n              Y,\n            \n            \n              Lertmaharit\n              S,\n            \n            \n              Wuttirattanakowit\n              N.\n            \n          \n          Cytokine levels in patients with Chikungunya virus infection.\n\t\t\t\t\tAsian Pac J Trop Med.\n\t\t\t\t\t2013;\n\t\t\t\t\t6:\n\t\t\t\t\t631\u2013\n\t\t\t\t\t634.","DOI":"10.1016\/S1995-7645(13)60108-X"},{"key":"2021051818503243700_i2590-017X-4-2-79-b41","doi-asserted-by":"crossref","unstructured":"Zheng\n              J,\n            \n            \n              Shi\n              Y,\n            \n            \n              Xiong\n              L,\n            \n            et al.\n          \n          The expression of IL-6, TNF-\u03b1, and MCP-1 in respiratory viral infection in acute exacerbations of chronic obstructive pulmonary disease.\n\t\t\t\t\tJ Immunol Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t2017:\n\t\t\t\t\t8539294.","DOI":"10.1155\/2017\/8539294"},{"key":"2021051818503243700_i2590-017X-4-2-79-b42","doi-asserted-by":"crossref","unstructured":"Angulo\n              J,\n            \n            \n              Mart\u00ednez-Valdebenito\n              C,\n            \n            \n              Marco\n              C,\n            \n            et al.\n          \n          Serum levels of interleukin-6 are linked to the severity of the disease caused by Andes virus.\n\t\t\t\t\tPLoS Negl Trop Dis.\n\t\t\t\t\t2017;\n\t\t\t\t\t11:\n\t\t\t\t\te0005757.","DOI":"10.1371\/journal.pntd.0005757"},{"key":"2021051818503243700_i2590-017X-4-2-79-b43","doi-asserted-by":"crossref","unstructured":"Erg\u00f6n\u00fcl\n              \u00d6,\n            \n            \n              \u015eeref\n              C,\n            \n            \n              Eren\n              \u015e,\n            \n            et al.\n          \n          Cytokine response in Crimean-Congo hemorrhagic fever virus infection.\n\t\t\t\t\tJ Med Virol.\n\t\t\t\t\t2017;\n\t\t\t\t\t89:\n\t\t\t\t\t1707\u2013\n\t\t\t\t\t1713.","DOI":"10.1002\/jmv.24864"},{"key":"2021051818503243700_i2590-017X-4-2-79-b44","doi-asserted-by":"crossref","unstructured":"Rollenhagen\n              C,\n            \n            \n              Asin\n              SN.\n            \n          \n          Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-menopausal women correlates with increased inflammatory responses.\n\t\t\t\t\tMucosal Immunol.\n\t\t\t\t\t2011;\n\t\t\t\t\t4:\n\t\t\t\t\t671\u2013\n\t\t\t\t\t681.","DOI":"10.1038\/mi.2011.34"},{"key":"2021051818503243700_i2590-017X-4-2-79-b45","doi-asserted-by":"crossref","unstructured":"Pacheco\n              JM,\n            \n            \n              Smoliga\n              GR,\n            \n            \n              O'Donnell\n              V,\n            \n            et al.\n          \n          Persistent foot-and-mouth disease virus infection in the nasopharynx of cattle; tissue-specific distribution and local cytokine expression.\n\t\t\t\t\tPLoS One.\n\t\t\t\t\t2015;\n\t\t\t\t\t10:\n\t\t\t\t\te0125698.","DOI":"10.1371\/journal.pone.0125698"},{"key":"2021051818503243700_i2590-017X-4-2-79-b46","doi-asserted-by":"crossref","unstructured":"Choudhary\n              MM,\n            \n            \n              France\n              TJ,\n            \n            \n              Teknos\n              TN,\n            \n            \n              Kumar\n              P.\n            \n          \n          Interleukin-6 role in head and neck squamous cell carcinoma progression.\n\t\t\t\t\tWorld J Otorhinolaryngol Head Neck Surg.\n\t\t\t\t\t2016;\n\t\t\t\t\t2:\n\t\t\t\t\t90\u2013\n\t\t\t\t\t97.","DOI":"10.1016\/j.wjorl.2016.05.002"},{"key":"2021051818503243700_i2590-017X-4-2-79-b47","doi-asserted-by":"crossref","unstructured":"Shin\n              H,\n            \n            \n              Wherry\n              EJ.\n            \n          \n          CD8 T cell dysfunction during chronic viral infection.\n\t\t\t\t\tCurr Opin Immunol.\n\t\t\t\t\t2007;\n\t\t\t\t\t19:\n\t\t\t\t\t408\u2013\n\t\t\t\t\t415.","DOI":"10.1016\/j.coi.2007.06.004"},{"key":"2021051818503243700_i2590-017X-4-2-79-b48","doi-asserted-by":"crossref","unstructured":"Luo\n              M,\n            \n            \n              Liu\n              J,\n            \n            \n              Jiang\n              W,\n            \n            et al.\n          \n          IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.\n\t\t\t\t\tJCI Insight.\n\t\t\t\t\t2020;\n\t\t\t\t\t5:\n\t\t\t\t\t139024.","DOI":"10.1172\/jci.insight.139024"},{"key":"2021051818503243700_i2590-017X-4-2-79-b49","doi-asserted-by":"crossref","unstructured":"Srirangan\n              S,\n            \n            \n              Choy\n              EH.\n            \n          \n          The role of interleukin 6 in the pathophysiology of rheumatoid arthritis.\n\t\t\t\t\tTher Adv Musculoskelet Dis.\n\t\t\t\t\t2010;\n\t\t\t\t\t2:\n\t\t\t\t\t247\u2013\n\t\t\t\t\t256.","DOI":"10.1177\/1759720X10378372"},{"key":"2021051818503243700_i2590-017X-4-2-79-b50","doi-asserted-by":"crossref","unstructured":"Pingen\n              M,\n            \n            \n              Bryden\n              SR,\n            \n            \n              Pondeville\n              E,\n            \n            et al.\n          \n          Host inflammatory response to mosquito bites enhances the severity of arbovirus infection.\n\t\t\t\t\tImmunity.\n\t\t\t\t\t2016;\n\t\t\t\t\t44:\n\t\t\t\t\t1455\u2013\n\t\t\t\t\t1469.","DOI":"10.1016\/j.immuni.2016.06.002"},{"key":"2021051818503243700_i2590-017X-4-2-79-b51","doi-asserted-by":"crossref","unstructured":"Beachboard\n              DC,\n            \n            \n              Horner\n              SM.\n            \n          \n          Innate immune evasion strategies of DNA and RNA viruses.\n\t\t\t\t\tCurr Opin Microbiol.\n\t\t\t\t\t2016;\n\t\t\t\t\t32:\n\t\t\t\t\t113\u2013\n\t\t\t\t\t119.","DOI":"10.1016\/j.mib.2016.05.015"},{"key":"2021051818503243700_i2590-017X-4-2-79-b52","doi-asserted-by":"crossref","unstructured":"Lan\n              T,\n            \n            \n              Chang\n              L,\n            \n            \n              Wu\n              L,\n            \n            \n              Yuan\n              YF.\n            \n          \n          IL-6 plays a crucial role in HBV infection.\n\t\t\t\t\tJ Clin Transl Hepatol.\n\t\t\t\t\t2015;\n\t\t\t\t\t3:\n\t\t\t\t\t271\u2013\n\t\t\t\t\t276.","DOI":"10.14218\/JCTH.2015.00024"},{"key":"2021051818503243700_i2590-017X-4-2-79-b53","doi-asserted-by":"crossref","unstructured":"Chen\n              LF,\n            \n            \n              Mo\n              YQ,\n            \n            \n              Jing\n              J,\n            \n            et al.\n          \n          Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.\n\t\t\t\t\tInt J Rheum Dis.\n\t\t\t\t\t2017;\n\t\t\t\t\t20:\n\t\t\t\t\t859\u2013\n\t\t\t\t\t869.","DOI":"10.1111\/1756-185X.13010"},{"key":"2021051818503243700_i2590-017X-4-2-79-b54","doi-asserted-by":"crossref","unstructured":"Guaraldi\n              G,\n            \n            \n              Meschiari\n              M,\n            \n            \n              Cozzi-Lepri\n              A,\n            \n            et al.\n          \n          Tocilizumab in patients with severe COVID-19: a retrospective cohort study.\n\t\t\t\t\tLancet Rheumatol.\n\t\t\t\t\t2020;\n\t\t\t\t\t2:\n\t\t\t\t\te474\u2013\n\t\t\t\t\te484.","DOI":"10.1016\/S2665-9913(20)30285-X"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/4\/2\/79\/2829132\/i2590-017x-4-2-79.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/4\/2\/79\/2829132\/i2590-017x-4-2-79.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:43Z","timestamp":1765475323000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/4\/2\/article-p79.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,29]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-20-27","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"type":"electronic","value":"2590-017X"},{"type":"print","value":"2666-2345"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}